Efficiency and safety of Varumin®
in treatment of
Sclerosis Multiplex (MS)

Clinical Hospital - Department of Neurology

Bitola 2007

Expert team:
1. D. Petrovski, MD
2. T. Hristovski, MD, Primarius
3. K. Petrovski, MD, Primarius
4. K. Pili-Kuzeva, MD, Primarius

Criteria for selection of patients for the study

(The Study was working on 10 Patients with Sclerosis Multiplex, 7 women and 3 men with different age)

Neurological status before beginning of the Study:

All patients have positive case-history on the disease, with many remissions of neurological symptoms.
Neurological status: all patients have present paresis of pyramidal type with Babinsky reflex (two patients with quadriparesis). They all have lost stomach skin reflex, 3 patients have expressed spasticity of the legs with heavy difficulties in moving. At 50% of the patients are present urination problems.
Disrupt of the sensibility is present at all patients, Lhermitte phenomena is present at 4 patients.
Eyesight nerve is engaged by one female patient and she has scotomas and transitory amblyopia (and also reduced vision).
Affection of vestibular system (spontaneous nistagmus) is present at 7 patients.
Difficulty in speech is present at one patient.
Intentional tremor is detected at 6 patients.
Cerebral symptomatology (ataxia, etc) is detected at 3 patients.
All patients have received Corticoid therapy several times.

Magnetic Resonance scans before the beginning of the Study

All patients with typically findings for the disease.

Way of use and dosage of Varumin®

Therapy was lasting one year and the way of use was as follows:
Because Varumin is solution for oral application and it contains from two glass bottles in the original package: Varumin 1 - 50 ml and Varumin 2 - 200 ml.
First, at the beginning of the treatment should be taken whole amount (50 ml) of Varumin 1 (in the morning, before meal). After 6 hour is beginning to take Varumin 2. It is taking 4 times a day one soup spoon before meal as long as the whole bottle (200 ml) was finished. It last about 5-6 days. After that next morning is continuing with taking first Varumin 1 and than again Varumin 2 by the up mentioned procedure.
At the time of the existing the treatment the patients were designated at specific regime of diet under the recommendation of the producer of the medicine.
In the same time while taking the medicine patients are also using Varumin herbal tea in the time between taking the medicine.
In the time of taking Varumin, patients were not taking any Corticoid therapy, neither any other immunological or vitamin therapy.

Presentation of cases

magnetic resonance before therapy



magnetic resonance after therapy with Varumin







magnetic resonance before therapy



magnetic resonance after therapy with Varumin



magnetic resonance before therapy



magnetic resonance after therapy with Varumin



SAFETY

At all patients was established good toleration without side effects that could be reason for stopping with therapy.

CONCLUSION

- From the whole trial we can make conclusion that at all patients have visible improvement of the general condition and neurological functions.

- Improvement of the functionality

- Efficiency of Varumin® was established after the second month and it is continuous during the whole therapy.

- Varumin® has excellent safety profile.

Expert team:

Dragan Petrovski, MD

Tome Hristovski, MD, Primarius

Kosta Petrovski, MD, Primarius

Kaliopi Pili – Kuzeva, MD, Primarius

Clinical Hospital "Dr. Trifun Panovski"- Bitola